Marie-Helene Horellou
Overview
Explore the profile of Marie-Helene Horellou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tardy-Poncet B, De Maistre E, Pouplard C, Presles E, Alhenc-Gelas M, Lasne D, et al.
J Thromb Haemost
. 2021 Apr;
19(8):1959-1972.
PMID: 33872452
Background: Diagnosis of heparin-induced thrombocytopenia (HIT) requires pretest probability assessment and dedicated laboratory assays. Objective: To develop a pretest score for HIT. Design: Observational; analysis of prospectively collected data of...
2.
Tardy-Poncet B, Montmartin A, Piot M, Alhenc-Gelas M, Nguyen P, Elalamy I, et al.
Biomedicines
. 2021 Apr;
9(4).
PMID: 33806140
Reliable laboratory diagnosis of heparin-induced thrombocytopenia (HIT) remains a major clinical concern. Immunoassays are highly sensitive, while confirmatory functional tests (based on heparin-dependent platelet activation) lack standardization. We evaluated the...
3.
Jourdi G, Lobies S, Kosmider O, Duchemin J, Audureau E, Conard J, et al.
Thromb Haemost
. 2020 Sep;
121(2):246-249.
PMID: 32932543
No abstract available.
4.
Hugon-Rodin J, Horellou M, Conard J, Gompel A, Plu-Bureau G
Thromb Haemost
. 2018 Apr;
118(5):922-928.
PMID: 29614525
Objective: This article estimates the interaction between types of combined hormonal contraception (CHC) and factor V Leiden (FVL) mutation on the risk of venous thrombosis event (VTE). Subjects And Methods:...
5.
Hugon-Rodin J, Horellou M, Conard J, Gompel A, Plu-Bureau G
J Endocr Soc
. 2017 Dec;
1(6):762-771.
PMID: 29264528
Context: In UK and French, but not World Health Organization (WHO), guidelines for combined hormonal contraception (CHC), family history of a venous thromboembolism (VTE) is a condition for which the...
6.
Hugon-Rodin J, Horellou M, Conard J, Flaujac C, Gompel A, Plu-Bureau G
Medicine (Baltimore)
. 2017 Aug;
96(34):e7734.
PMID: 28834877
Information on the clinical and biological characteristics of combined hormonal contraceptives (CHC) users experiencing a venous thromboembolism (VTE) event is scarce. Better knowledge of factors determining the VTE risk in...
7.
Alhenc-Gelas M, Plu-Bureau G, Hugon-Rodin J, Picard V, Horellou M
Thromb Haemost
. 2017 Mar;
117(6):1040-1051.
PMID: 28300866
Inherited quantitative (type I) or qualitative (type II) antithrombin deficiency (ATD) due to mutations in the SERPINC1 gene is a well-known risk factor for venous thromboembolism. ATD may also increase...
8.
Calmette L, Ibrahim F, Gouin I, Horellou M, Mazoyer E, Fontenay M, et al.
Ann Biol Clin (Paris)
. 2017 Jan;
75(1):93-100.
PMID: 28132949
Samples transported by pneumatic tube system are submitted to forces of acceleration and deceleration which can affect laboratory parameters. At Cochin hospital, majority of samples of hemostasis, except for platelets...
9.
Ibrahim F, Calmette L, Layka A, Horellou M, Mazoyer E, Gouin-Thibault I, et al.
Ann Biol Clin (Paris)
. 2016 Aug;
74(4):457-64.
PMID: 27492699
The proposals of the Working group on perioperative hemostasis (Groupe d'intérêt en hémostase péri-opératoire (GIHP)) concerning the perioperative management of patients receiving the direct oral anticoagulants (DOACs) are based on...
10.
Godier A, Martin A, Leblanc I, Mazoyer E, Horellou M, Ibrahim F, et al.
Thromb Res
. 2015 Aug;
136(4):763-8.
PMID: 26319422
Background: Peri-procedural management of direct oral anticoagulants (DOAC) is challenging. The optimal duration of pre-procedural discontinuation that guarantees a minimal DOAC concentration ([DOAC]) at surgery is unknown. The usual 48-hour...